NYSE · Healthcare
ADC Therapeutics SA (ADCT)
As-reported financials and recent SEC filings for ADC Therapeutics SA, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$81.4M
Net income
$-142.6M
Net margin
—
Diluted EPS
$-1.12
ROE
76.7%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2023 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $81.4M | $70.8M | $69.6M | $209.9M | — |
| Gross profit | — | $64.9M | — | — | — |
| Operating income | $-121.5M | $-130.7M | $-166.0M | $-123.3M | — |
| Net income | $-142.6M | $-157.8M | $-240.1M | $-157.1M | — |
| Diluted EPS | $-1.12 | $-1.62 | $-2.94 | $-2.01 | — |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-07-02
View on EDGAR →42026-07-02
View on EDGAR →42026-07-02
View on EDGAR →42026-07-02
View on EDGAR →8-K2026-07-02
View on EDGAR →8-K2026-06-24
View on EDGAR →42026-06-03
View on EDGAR →42026-06-03
View on EDGAR →Largest Healthcare peers
Go deeper on ADCT
Search ADC Therapeutics SA’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.